Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialArjun Vasant Balar, Dean F. Bajorin, Matthew D. Galsky et al.|The Lancet|2016Cited by 2.2k
Intermittent versus Continuous Androgen Deprivation in Prostate CancerMaha Hussain, Ian M. Thompson, Peter Venner et al.|New England Journal of Medicine|2013Cited by 568
Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid FeaturesBradley A. McGregor, Toni K. Choueiri, Rana R. McKay et al.|Journal of Clinical Oncology|2019Cited by 147
Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer PatientsUlka N. Vaishampayan, Lawrence G. Lum|Prostate Cancer|2015Cited by 62
A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancerMohamed A. Gouda, Funda Meric‐Bernstam, Martin H. Voss et al.|ESMO Open|2025Cited by 54